Filippo Antonini

Dr. Filippo Antonini

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2016 in World Journal of Gastrointestinal Pathophysiology
Verified
Journal Article
Open access
FAFilippo Antonini
Filippo Antonini
RPRaffaele Pezzilli
Raffaele Pezzilli
LALucia Angelelli
Lucia Angelelli
GMGiampiero Macarri
Giampiero Macarri
Pancreatic disorders in inflammatory bowel disease

1 January 2019 in Endoscopic Ultrasound
Verified
Journal Article
Open access
FAFilippo Antonini
Filippo Antonini
GDGabriele Delconte
Gabriele Delconte
LFLorenzo Fuccio
Lorenzo Fuccio
GNGermana de Nucci
Germana de Nucci
CFCarlo Fabbri
Carlo Fabbri
GMGiampiero Macarri
Giampiero Macarri
Background and Objective: A new 20-gauge?(G) biopsy needle with a core-trap technology has been developed with a large core size and enhanced flexibility. The aim of this multicenter study was to determine the feasibility, efficacy, and safety of EUS-guided fine-needle biopsy?(EUS-FNB) with the new 20G needle in diagnosing subepithelial lesions?(SELs). Materials and Methods: Retrospectively collected data from consecutive patients with SELs undergoing EUS-FNB with the 20G needle at five centers were analyzed. Results: A total of 50 SELs were included. The mean lesion size was 43.1?±?17.5?mm. The lesion locations were esophagus?(n?=?1), stomach?(n?=?37), distal duodenum?(n?=?5), rectum?(n?=?6), and colon?(n?=?1). The procedure was technically feasible in all patients. Definitive diagnosis with full histological assessment including immunohistochemistry was obtained in 88%?(44/50) of the patients. Considering malignant versus benign lesions, the sensitivity, specificity, positive predictive value, and negative predictive value were 85%?(95% confidence interval?[CI] 70.2–94.3), 100%?(95% CI 58.7%–100%), 100%?(95% CI 85.1%–100%), and 62.5?(95% CI 27.7–84.8), respectively. No major complications requiring additional care have been observed. Conclusions: In this multicenter study, we found that EUS-FNB with the new 20G core needle is an effective and safe method for the diagnosis of SELs with a high rate of producing adequate histological material and high diagnostic accuracy even from difficult-to-approach anatomical locations.

1 February 2020 in Digestive and Liver Disease
Verified
Journal Article
Closed access
RMRoberto Di Mitri
Roberto Di Mitri
FMFilippo Mocciaro
Filippo Mocciaro
FAFilippo Antonini
Filippo Antonini
DSDaniela Scimeca
Daniela Scimeca
ECElisabetta Conte
Elisabetta Conte
CFCarlo Fabbri
Carlo Fabbri

25 October 2023 in Digestive Endoscopy
Verified
Journal Article
Open access
ALAndrea Lisotti
Andrea Lisotti
ACAnna Cominardi
Anna Cominardi
MBMaria Cristina Conti Bellocchi
Maria Cristina Conti Bellocchi
SCStefano Francesco Crinò
Stefano Francesco Crinò
ALAlberto Larghi
Alberto Larghi
TGthe REUBIO Study Group
the REUBIO Study Group
Objectives: Repeated endoscopic ultrasound (EUS)‐guided tissue acquisition represents the standard practice for solid pancreatic lesions after previous nondiagnostic or inconclusive results. Since data are lacking, we aimed to evaluate the diagnostic performance of repeated EUS fine‐needle biopsy (rEUS‐FNB) in this setting. The primary outcome was diagnostic accuracy; sample adequacy, sensitivity, specificity, and safety were secondary outcomes.Methods: Consecutive patients undergoing rEUS‐FNB for solid pancreatic lesions at 23 Italian centers from 2019 to 2021 were retrieved. Pathology on the surgical specimen, malignant histology together with ≥6‐month follow‐up, and benign pathology together with ≥12‐month follow‐up were adopted as gold standards.Results: Among 462 patients, 56.5% were male, with a median age of 68 (59–75) years, malignancy prevalence 77.0%. Tumor size was 26 (20–35) mm. Second‐generation FNB needles were used in 89.6% cases. Diagnostic accuracy, sensitivity, and specificity of rEUS‐FNB were 89.2%, 91.4%, and 81.7%, respectively (19 false‐negative and 12 false‐positive results). On multivariate analysis, rEUS‐FNB performed at high‐volume centers (odds ratio [OR] 2.12; 95% confidence interval [CI] 1.10–3.17; P = 0.03) and tumor size (OR 1.03; 95% CI 1.00–1.06; P = 0.05) were independently related to diagnostic accuracy. Sample adequacy was 94.2%. Use of second‐generation FNB needles (OR 5.42; 95% CI 2.30–12.77; P < 0.001) and tumor size >23 mm (OR 3.04; 95% CI 1.31–7.06; P = 0.009) were independently related to sample adequacy.Conclusion: Repeated EUS‐FNB allowed optimal diagnostic performance after nondiagnostic or inconclusive results. Patients' referral to high‐volume centers improved diagnostic accuracy. The use of second‐generation FNB needles significantly improved sample adequacy over standard EUS‐FNB needles.

1 August 2017 in Digestive and Liver Disease
Verified
Journal Article
Closed access
FAFilippo Antonini
Filippo Antonini
LFLorenzo Fuccio
Lorenzo Fuccio
SGSara Giorgini
Sara Giorgini
CFCarlo Fabbri
Carlo Fabbri
LFLeonardo Frazzoni
Leonardo Frazzoni
GMGiampiero Macarri
Giampiero Macarri

20 January 2015 in Endoscopy
Verified
Journal Article
Closed access
PDF file
FAFilippo Antonini
Filippo Antonini
LALucia Angelelli
Lucia Angelelli
CRCorrado Rubini
Corrado Rubini
GMGiampiero Macarri
Giampiero Macarri
A 59-year-old man with a history of diabetes mellitus and smoking was referred for the evaluation of weight loss and abdominal discomfort. Abdominal computed tomography revealed mild ascites, multiple liver nodules, hepatic hilar lymphadenopathy, and a 60 × 50-mm solid exophytic mass in the pancreatic body ([Fig. 1]). The serum lipase, transaminase, bilirubin, alpha-fetoprotein (AFP), chromogranin A, cancer antigen (CA) 19-9, and carcinoembryonic antigen (CEA) levels were within normal range. Endoscopic ultrasound-guided fine-needle biopsy (EUS-FNB) of the pancreatic mass was performed with a 19-gauge ProCore needle (Cook Medical, Winston-Salem, North Carolina, USA) ([Fig. 2]). On histologic examination, the specimen exhibited monomorphic neoplastic cells, with moderate atypia and occasional mitoses, arranged in solid nests and a trabecular pattern. The cells had indistinct cytoplasmic borders, large central oval nuclei, occasional nucleoli, and abundant eosinophilic cytoplasm, with the appearance of hepatocellular carcinoma (HCC) ([Fig. 3]). No bile production was identified. The tumor cells reacted strongly with Hep Par 1 and were negative for chromogranin, synaptophysin, AFP, cytokeratin (CK) 7, and CK20 ([Fig. 4]). Primary pancreatic hepatoid carcinoma or metastatic/ectopic HCC was suspected. Sorafenib (Nexavar; Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals) at a reduced dose of 200 mg twice daily was commenced and produced a short-term clinical benefit. The patient’s condition then quickly deteriorated, hepatic failure developed, and he died 4 months after the diagnosis. Pancreatic hepatoid carcinoma is an uncommon neoplasm sharing morphologic and immunohistochemical features with HCC. It seems to originate from ectopic liver tissue located in various organs, including the pancreas. Specifically, pancreatic hepatoid carcinoma, despite its morphologic appearance of a well-differentiated carcinoma, is a very aggressive neoplasm that is often associated with liver and lymph node metastases at the time of diagnosis, mimicking a metastatic HCC [1] [2] [3]. In this case, histologic typing was obtained by EUS-FNB of the pancreatic mass, after which immunohistochemistry and the clinical behavior led to a diagnosis of pancreatic hepatoid carcinoma. Endoscopy_UCTN_Code_CCL_1AF_2AZ